RE:Aristotle® to the market by Q1 2021.Jonnyboy85 wrote: The focus of the Company is on the following:
Being first to market with a pan-cancer test – Aristotle® - with the capability of screening for multiple cancers, with high sensitivity and specificity, from a single sample of blood.
COVID-19 has severely disrupted business and has created both problems and opportunities. For the Company it has accelerated many of the systems and processes which the Company was putting into place prior to the COVID-19 pandemic such as telehealth. COVID-19 has created significant revenue opportunities for the Company but, more importantly, it has brought multiple new, large companies, healthcare groups as well as government groups to work with the Company in an accelerated timeframe. Although these groups require COVID-19 testing, they are also interested in Aristotle®.
The Company plans on introducing Aristotle® to the market by Q1 2021.